Forbion — 2022 Investments
3 investments dated 2022 · listed companies and verified rows first · show all
F2G develops medicines to treat serious fungal diseases where existing therapies have failed or are ineffective.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsAdvent Life SciencesAisling CapitalAMR Action FundAstellas Venture Management LLCBrace PharmaSofinnova Partners+4 more
Portfolio company acquired by Novo Nordisk for $1.1B USD.
Co-investorsadMare BioInnovationsAmorChemGenesys CapitalJDRF T1D FundNew Enterprise Associates (NEA)Tarnagulla Ventures+2 more
Co-investorsBioMedPartnersHealthCapInkefPontifax Venture CapitalV-Bio Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.








